Nyxoah Reports Full Year 2020 Results


Nyxoah Reports Full Year 2020 Results

Conference call and webcast today at 3pm CET / 9am ET

Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ended December 31, 2020.

Olivier Taelman, Chief Executive Officer of Nyxoah, said: “2020 was a year marked by key accomplishments for Nyxoah, with important milestones showing focused execution across business units. Despite the Covid-19 pandemic, the impact on Nyxoah’s activities was limited and our manufacturing facilities remained operational, with sufficient production to meet our needs.”

Key Points

  • Financial
    • 25M€ round onboarding ResMed as new investor
    • 85M€ IPO on Euronext Brussels
  • Clinical
    • BETTER SLEEP study enrolment close of 42 implanted patients M6 data to be expected Q2 2021
    • IDE trial approval by FDA in June 2020, with first US and international implants by end 2020
    • EliSA implants on 15 patients for long term safety & efficacy, trial expected to follow patients over a five-year period
  • Commercial
    • Germany G-BA approving NUB reimbursement at a similar reimbursement level as other neurostimulation-based OSA therapies
    • First revenue generation in Germany
  • Operational
    • No production stop despite COVID
    • Tech transfer to a second independent manufacturing site in Belgium started
  • R&D
    • MRI compatibility full body 1.5T and 3T
    • Next Gen of Genio system with improved features for the implantable and external components

Highlights of 2020

  • In 2020, the Company continued to advance its goal of further expanding its footprint and providing more patients suffering from OSA access to the Genio® solution, thereby addressing a significant current unmet medical need.
  • The German federal joint committee (G-BA) confirmed in March 2020 that the Genio® system is entitled to join the existing NUB for hypoglossal nerve stimulation (“HGNS”) systems at a similar reimbursement level as other neurostimulation-based OSA therapies. As a result, the Company generated its first commercial revenue in 2020, albeit that such revenue was limited due to the NUB-specific negotiation path. As of 2021, the reimbursement will move away from NUB into a DRG system which should allow the Company to fully ramp up its German commercialization strategy.
  • Despite Covid-19 related disruptions, the Company was able to continue producing Genio® devices in sufficient quantities to meet needs.

Clinical development

  • In November 2020, the Company completed enrolments in the BETTER SLEEP trial, conducted in Australia. In total, 42 patients were enrolled in this pre-marketing study, designed to assess the safety and efficacy / performance of the Genio® system for the treatment of OSA in adult patients who either exhibit or do not exhibit a complete concentric collapse (“CCC”) of the soft palate. The study is planned to have a 36-month follow-up and the end of the study is expected by the end of 2023. Six-month follow-up results are expected to be available in the second quarter of 2021.
  • If the primary endpoints of this study are reached, the Company plans to request a therapy indication expansion that would allow the Genio system to be used to treat CCC patients that are currently excluded from HGNS. In the meantime, the discussion with the European notified bodies has been initiated. If the Company obtains marketing authorization for the Genio system in the US, the Company plans to leverage the clinical data from the BETTER SLEEP study to expand the authorized indication to include the treatment of CCC patients in the US.
  • In 2020, enrolment continued, but was slowed down due to Covid-19, in the EliSA trial, the Company’s multicenter post-marketing trial being conducted throughout Europe which is designed to gather long-term safety and clinical data regarding the Genio® system in adult patients suffering from moderate-to-severe OSA. As of 31 December 2020, 15 patients out of the total intended 110 patients were enrolled in the study coming from five different countries (Germany, Switzerland, France, the Netherland, Belgium).
  • In June 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application for the Company’s DREAM trial. This study aims to confirm the safety and effectiveness of the Genio® system and is designed to support marketing authorization of the Genio® system in the United States. The study will enroll 134 moderate-to-severe OSA patients who failed first line CPAP therapy. Up to 19 US sites in combination with 7 international sites have been selected to participate in the study. By the end of 2020, the first US and international implants took place.

Research and Development

  • Throughout 2020, the Company continued to invest in improving the Genio® system with a goal of developing next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance.
  • In 2020, the Company performed the Magnetic Resonance Imaging (“MRI”) compatibility testing of the Genio® system, resulting in CE mark and FDA conditional MR labeling approval in early 2021.

Financial highlights

  • In February 2020, the Company raised €25 million in a private financing round, whereby ResMed Inc. (NYSE:RMD; ASX:RMD), a world-leading digital health company in the OSA field, joined the Company as a new shareholder. All major shareholders at that time participated in this financing round onboarding ResMed Inc.
  • In September 2020, the Company raised €85 million ($100 million) as a result of the initial public offering (“IPO”) of new shares of the Company on Euronext Brussels under the symbol “NYXH”. The IPO resulted in an initial market capitalization of €375 million (taking into account the exercise in full of the over-allotment option in the framework of the IPO).

Subsequent Events

  • After the close of the financial year, the Company signed an exclusive license agreement with Vanderbilt University (Nashville, TN, USA). This agreement allows Nyxoah to develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions based on inventions and patents owned by Vanderbilt University, which could potentially expand Nyxoah’s future pipeline.
  • On February 22, 2021, the Company issued 10,000 shares pursuant to an exercise of subscription rights. Consequently, on the date of this Annual Report, the Company’s registered capital amounts to EUR 3,797,765.64, represented by 22.107.609 shares.

Outlook for 2021

Our business, operational, and clinical outlook for 2021 include the following:

  • Ramp up EU revenue and build a dedicated sales team in Germany
  • Obtain reimbursement in Switzerland
  • BETTER SLEEP trial 6 month results, basis for Complete Concentric Collapse (“CCC”) therapeutic indication expansion
  • Open second independent manufacturing site in Belgium, in addition to existing site in Israel
  • Complete DREAM pivotal trial enrollment

Full Year 2020 Financial Results
Income Statement

For the first time since its inception, the Company began generating revenue as of July 2020. The revenue of KEUR 69 was generated under the existing HGNS NUB coding in Germany. The total cost of goods sold was KEUR 30.

Operating costs increased to KEUR 11,224 in 2020 from KEUR 7,715 in 2019, or a change of KEUR 3,509, due to increases of activities in all departments. The Company is currently conducting three clinical trials to continue gathering clinical data and obtain regulatory approvals. In June 2020 the Company obtained FDA approval to start the DREAM study in the US. In line with its strategy, the Company continues investing in research and development to improve and develop the next generation of the Genio® system and preparing for scaling-up of production capacities.

General and administrative expenses increased by 78% to KEUR 7,522 in 2020 from KEUR 4,226 in 2019. The increase is due to consulting expenses, staff and legal fees to support the Company growth. The increase in consulting and contractors’ fees includes variable compensations of KEUR 1,981 related to a cash-settled share-based payment transaction (2019: KEUR 1,199). The increase of KEUR 159 in legal fees is due to services and not to any ongoing disputes.

Research and development expenses increased by 29% to KEUR 3,066 in 2020 from KEUR 2,375 in 2019, before capitalization of KEUR 2,593 in 2020, due to the increase of development costs of the Genio® system.  Research and development expenses consist of product development, engineering to develop and support our products, testing, consulting services and other costs associated with the next generation of the Genio® system that do not meet the development capitalization criteria. The Company continues to invest in improving the Genio® system to develop next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance. These expenses primarily include employee compensation and outsourced development expenses.

Clinical expenses increased by 50% to KEUR 4,316 in 2020 from KEUR 2,881 in 2019, before capitalization of KEUR 3,263 in 2020. The increase in the expenses was mainly due to an increase in staff and consulting to support the completion of the BETTER SLEEP study implantations, continuous recruitment for EliSA study and the launch of the new DREAM IDE study in the US. Clinical expenses consist of clinical studies related to the development of our Genio® system, consulting services and other costs associated with clinical activities. These expenses include employee compensation, clinical trial management and monitoring, payments to clinical investigators, data management and travel expenses for our various clinical trials.

Manufacturing expenses increased by 109% to KEUR 3,802 in 2020 from KEUR 1,812 in 2019, before capitalization of KEUR 3,342 in 2020. The increase in the expenses was mainly due to increases in staff for the production and engineering teams to support capacity and yield improvement, and also due to purchasing raw materials to support increase in the production. Manufacturing and operation expenses consist primarily of acquisition costs of the components of the Genio® system, scrap and inventory obsolescence as well as distribution-related expenses such as logistics and shipping costs.

Quality assurance and regulatory expenses increased by 58% to KEUR 1,474 in 2020 from KEUR 928 in 2019, before capitalization of KEUR 1,247 in 2020. The increase in the expenses was due to staff increases and QA & regulatory activities to support manufacturing scaling up process. Quality assurance and regulatory expenses consist primarily of quality control, quality assurance and regulatory expenses. These expenses include employee compensation, consulting, testing and travel expenses.

Therapy development expenses increased by 107% to KEUR 1,864 in 2020 from KEUR 902 in 2019. The increase in the expenses was due to an increase in staff and consulting to support the commercialization in Europe. Therapy development expenses consist of compensation for personnel, spending related to market access and reimbursement activities. Other therapy development expenses include training physicians, travel expenses, conferences and consulting services.

Balance Sheet

The Company started recognizing the development expenditure as an asset as of March 2019, triggered by obtaining CE mark. Development costs primarily include employee compensation and outsourced development expenses. In 2020, the Company had capitalized developments costs of KEUR 9,874.

Property, plant & equipment shows a total additional net book value of KEUR 391 at balance sheet date consequently to leasehold improvements in the Company’s offices in Belgium and Israel.  Right of use assets shows a total additional increase by KEUR 2,217 due to new leases signed in 2020.

Cash and cash equivalents show a total additional increase of KEUR 86,445. This increase was due to total capital raises of KEUR 103,583, net of transaction costs, in February 2020 and in September 2020 (Initial Public Offering (“IPO”)). Cash from financing activities was offset by cash used in the operating activities of KEUR 7,015 and cash used in the investing activities of KEUR 10,693.

The share capital and the share premium have increased, respectively, by KEUR 1,315 and KEUR 103,268 due to the capital increases in cash in 2020 for a total amount KEUR 103,583, net of transaction costs and capital increase in kind (conversion of loan in shares) of KEUR 1,000.

Lease liabilities shows a total additional increase of KEUR 2,242 due to new lease agreements in Belgium and Israel.

Other non-current and current payables have increased by KEUR 1,303 from KEUR 2,820 to KEUR 4,123 due higher cash-settled share-based payment liability of KEUR 473, higher accrued expenses of KEUR 557 and higher payroll related payables of KEUR 134.

Cash Flow Statement

The net cash burn rate for 2020 is a net cash inflow amounting to KEUR 86,445 compared to a net cash outflow of KEUR 10,950 for 2019.

The cash outflow resulting from operating activities amounted to KEUR 7,015 in 2020 compared to KEUR 5,965 in 2019. An increase of cash outflow of KEUR 1,050 due to KEUR 3,768 higher losses mainly from increased general and administrative expenses and therapy development expenses and higher interest and tax paid, net of KEUR 166, offset by KEUR 2,421 higher non-operating cash adjustments (KEUR 2,202 higher share-based payment expense) and a positive variation in the working capital of KEUR 463.

Cash flow from investing activities represented a net cash outflow of KEUR 10,693 for 2020. An increase of KEUR 4,898 compared to 2019 mainly explained by higher capitalization of development expenses in 2020.

The increase in cash inflow from financing activities is primarily due to the IPO completed in September 2020 and the proceeds from the February 2020 capital raise.

Financial Information

The consolidated financial statements have been prepared in accordance with IFRS as adopted by the EU. The financial information included in this press release is an extract of the full IFRS consolidated financial statements, which will be published on 9 April 2021. The statutory auditor, EY Bedrijfsrevisoren /Réviseurs d'Entreprises SRL, represented by Carlo-Sébastien D'Addario, has issued an unqualified audit opinion with emphasis of matter paragraph relating to a restatement for the year 2019 and the balance at 1 January 2019 to reflect the adjustments relating to a share based compensation accrual.

2021 Financial & Events Calendar

  • 09 April 2021                               Full Year 2020 Financial and Operating Results & Annual Report
  • 09 June 2021                              Annual Shareholders’ Meeting
  • 31 August 2021                          Interim Financial Report H1, 2021
  • 14-15 September 2021           Baird 2021 Global Healthcare Conference (virtual)

Conference Call & Webcast
Nyxoah will host a conference call with live webcast today at 3pm CET/9am ET. The webcast may be accessed on the Events page of the company’s website or by clicking here. A replay of the webcast will be available on the Nyxoah website.

For further information, please contact:
Fabian Suarez, Chief Financial Officer
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal
law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other

factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such
forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Consolidated Income Statement

For the year ended 31 December
 (in EUR 000) 20202019
Restated *
Revenue 69 -
Cost of goods sold (30) -
Gross Profit39 -
General and administrative expenses (7,522) (4,226)
Research and development expenses (473) (630)
Clinical expenses (1,053) (848)
Manufacturing expenses (460) (489)
Quality assurance and regulatory expenses (227) (227)
Patents Fees & Related (123) (267)
Therapy Development expenses (1,864) (902)
Other operating income/ (expenses) 459 (126)
Operating loss for the period(11,224)(7,715)
Financial income 62 71
Financial expense (990) (740)
Loss for the period before taxes (12,152) (8,384)
Taxes (93) (70)
Loss for the period(12,245)(8,454)
Loss attributable to equity holders1(12,245)(8,454)
Other comprehensive (loss) / income
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (58) 168
Total comprehensive loss for the year, net of tax(12,303)(8,286)
Loss attributable to equity holders1(12,303)(8,286)
Basic Earnings Per Share (in EUR) (0.677) (0.568)
Diluted Earnings Per Share (in EUR) (0.677) (0.568)

Consolidated Statement of Financial Position

As of and for the year ended 31 December
 (in EUR 000) 20202019
Non-current assets
Property, plant and equipment 713 322
Intangible assets 15,853 5,734
Right of use assets 3,283 1,066
Deferred tax asset 32 21
Other long-term receivables 91 78
Current assets
Inventory 55 -
Trade receivables - 60
Other receivables 1,644 2,048
Other current assets 109 11
Cash and cash equivalents 92,300 5,855
Total assets114,08015,195

Capital and reserves
Capital 3,796 2,481
Share premium 150,936 47,668
Share based payment reserve 2,650 420
Currency translation reserve 149 207
Retained Earnings (60,341) (48,415)
Total equity attributable to shareholders97,1902,361
Non-current liabilities
Financial debt 7,607 7,146
Lease liability 2,844 735
Pension Liability 37 30
Other payables - 547
Current liabilities
Financial debt 616 378
Lease liability 473 340
Trade payables 1,190 1,385
Other payables 4,123 2,273
Total liabilities16,89012,834
Total equity and liabilities114,08015,195


* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3

Consolidated Statement of Cash Flows

For the year ended 31 December
 (in EUR 000) 20202019
Restated *
Loss before tax for the year(12,152)(8,384)
Adjustments for:
Finance income (62) (71)
Finance expenses 990 740
Depreciation and impairment of property, plant
and equipment and right-of-use assets
620 433
Share-based payment transaction expense 2,549 346
Pension-related expenses 7 30
Other non-cash items2 (134) 70
Cash generated before changes in working capital(8,182)(6,836)
Changes in working capital:
Increase in Inventory (55) -
Decrease/(Increase) in Trade and other receivables 365 (1,385)
     Increase in Trade and other payables 1,109 2,342
Cash generated from changes in operations(6,763)(5,879)
Interests received 3 8
Interests paid (151) (33)
Income tax paid (104) (61)
Net cash used in operating activities(7,015)(5,965)
Purchases of property, plant and equipment (562) (51)
Capitalization of intangible assets (10,118) (5,734)
 Increase of long-term deposits (13) (10)
Net cash used in investing activities(10,693)(5,795)
Payment of principal portion of lease liabilities (479) (341)
Repayment of other loan (63) (82)
Recoverable cash advance received 190 1,196
Repayment of recoverable cash advance (55) (40)
Proceeds from convertible loan 1,000 -
Proceeds from issuance of shares, net of transaction costs 103,583 -
Net cash generated/(used) from financing activities104,176733
Movement in cash and cash equivalents86,468(11,027)
Effect of exchange rates on cash and cash equivalents (23) 77
Cash and cash equivalents at 1 January5,85516,805
Cash and cash equivalents at 31 December92,3005,855

Consolidated Statement of Changes in Equity

Attributable to owners of the parent
 (in EUR 000) 

CapitalShare premiumShare based payment reserveCurrency translation reserveRetained earningsTotal
Balance at 1 January 2019* restated2,48147,6688039(39,967)10,301
Loss for the year (8,454) (8,454)
Other comprehensive income for the year 168 168
Total comprehensive income/(loss) for the year168(8,454)(8,286)
Equity-settled share-based payment plan 340 6 346
Total transactions with owners of the Company recognized directly in equity3406346
Balance at 31 December 2019 restated *2,48147,668420207(48,415)2,361
Balance at 1 January 2020 restated *2,48147,668420207(48,415)2,361
Loss for the year (12,245) (12,245)
Other comprehensive loss for the year (58) (58)
Total comprehensive loss for the year---(58)(12,245)(12,303)
Equity-settled share-based payment plan 2,230 319 2,549
Issuance of shares for cash 1,304 108,857 110,161
Issuance of shares in kind 11 989 1,000
Transaction cost (6,578) (6,578)
Total transactions with owners of the Company recognized directly in equity1,315103,2682,230319107,132
Balance at 31 December 20203,796150,9362,650149(60,341)97,190


* The year 2019 and the balance at 1 January 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3

1 For the years ending 31 December 2020 and 2019, the loss is fully attributable to equity holders of the Company as the Company does not have any non-controlling interests.
* The year 2019 has been restated to reflect the adjustments as explained in Note ‎5.2.3

2 The other non-cash items include (i) the impact of the initial measurement and re-measurement of recoverable cash advances (see our 2020 Annual Report notes ‎5.14  ,‎5.24 and (ii) the evolution of the deferred tax assets.
* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

NEP’s Solution for Aurora, North One and Extreme E Tests Its Metal In Some of the World’s Harshest Conditions13.4.2021 19:21:56 CEST | Press release

SHOWCASING CUTTING EDGE TECHNOLOGY & SUSTAINABILITY WORKING TOGETHER LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Last weekend marked the first event for Extreme E, a new all-electric off-road racing series designed to highlight the climate crisis. NEP Group, the leading technical partner for content producers around the globe, worked with Extreme E and host broadcaster Aurora Media Worldwide and North One, to create a cutting-edge, sustainable broadcast solution that brought the first race, in AlUla, Saudi Arabia, into homes in 180 countries around the globe. Designed to mirror Extreme E’s goals of marrying the latest technology with sustainability and building solutions to meet the rigors of the world’s harshest conditions, NEP’s innovative broadcast services will be used by Aurora and North One at races in Senegal, Greenland, Brazil and Patagonia as the series continues. NEP’s complete end-to-end broadcast package includes a custom IP flypack, remote production solutions, crewing, sat

Annual General Meeting 2021: Tecan shareholders endorse all motions proposed by the Board of Directors13.4.2021 17:45:00 CEST | Press release

Votes cast exclusively through the independent proxy in line with COVID-19 Ordinance 3 of the Swiss government to combat the pandemicIncrease in the dividend from CHF 2.20 to CHF 2.30 per share Lukas Braunschweiler, Heinrich Fischer, Oliver Fetzer, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chairman of the BoardChrista Kreuzburg, Oliver Fetzer and Daniel R. Marshak confirmed as members of the Compensation CommitteeAll proposals relating to compensation approved Männedorf, Switzerland, April 13, 2021 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors on April 13, 2021. The Annual General Meeting was held at the headquarters of the company, without personal attendance by shareholders. Voting rights could only be exercised through the independent proxy in line with the Federal Act on the Statutory Pri

Stockwik offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier13.4.2021 17:31:00 CEST | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDANT OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA FÖRESKRIFTER ELLER KRÄVA REGISTRERING ELLER LIKNANDE ÅTGÄRDER. VÄNLIGEN SE VIKTIG INFORMATION I SLUTET AV PRESSMEDDELANDET. Stockwik Förvaltning AB (publ) (”Stockwik” eller ”Bolaget”) offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier till svenska och internationella institutionella investerare (den ”Riktade Nyemissionen”). Bolaget avser att genomföra den Riktade Nyemissionen med avvikelse från aktieägarnas företrädesrätt med stöd av bemyndigandet från årsstämman den 8 maj 2020. Stockwik har gett Pareto Securities AB (”Pareto Securities”) i uppdrag att utreda förutsättningarna för att genomföra den Riktade Nyemissionen genom

Stockwik announces intention to carry out a directed new share issue of up to 1,026,055 new shares13.4.2021 17:31:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Stockwik Förvaltning AB (publ) (”Stockwik” or the ”Company”) hereby announces intention to carry out a directed new share issue of up to 1,026,055 new shares directed to Swedish and international institutional investors (the “Directed New Share Issue”). The Company intends to carry out the Directed New Share Issue with deviation from the shareholders' preferential rights pursuant to the authorization granted by the annual general meeting on 8 May 2020. Stockwik has engaged Pareto Securities AB (“Pareto Securities”) to investigate the conditions to carry out the Directed New Shar

Norsk Hydro: Innkalling til generalforsamling 202113.4.2021 16:27:22 CEST | Pressemelding

Aksjeeierne i Norsk Hydro ASA innkalles til ordinær Generalforsamling torsdag 6. mai 2021 kl. 10:00. Generalforsamlingen vil i år gjennomføres digitalt med elektronisk stemmegivning som følge av Covid-19 situasjonen. Se vedlagt guide for online deltakelse. Det er også mulig å forhåndsstemme eller gi fullmakt før møtet. Fullstendig innkalling, agenda og vedlegg er vedlagt. Alle relevante dokumenter ligger på Investorkontakt Line Haugetraa +47 41406376 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg Arsberetning og arsregnskap 2020Guide for digital deltakelseHydros lonnspolitikkInnkalling til ordinaer generalforsamling 2021Innstilling fra Valgkomiteen 2021Moteseddel

Norsk Hydro: Notice of Annual General Meeting 202113.4.2021 16:27:22 CEST | Press release

Notice is given that the Annual General Meeting of Norsk Hydro ASA will be held on Thursday 6 May 2021 at 10:00 (CEST). Please be informed that the Annual General Meeting will be held as a digital meeting with electronic voting due to the Covid-19 situation. Please refer to the attached guide for online participation. It is also possible to vote in advance or attend the meeting by proxy. The full notice, agenda and appendices are attached. All relevant documents can be found on Investor contact: Line Haugetraa +47 41406376 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments Financial Statements and Board of Directors report 2020Guideline for online participationHydro remuneration policyNotice of General Meeting 2021Recommendation from the Nomination Committee 2021Voting instructions

Kallelse till årsstämma i Stockwik Förvaltning AB (publ)13.4.2021 16:00:00 CEST | Pressemelding

Aktieägarna i Stockwik Förvaltning AB (publ), org. nr 556294-7845, kallas härmed till årsstämma fredagen den 14 maj 2021 kl. 10:00. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter och råd om undvikande av sammankomster har styrelsen med stöd av tillfälliga lagregler beslutat att årsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. FÖRUTSÄTTNINGAR FÖR DELTAGANDE Den som önskar att genom poströstning delta i årsstämman ska dels vara upptagen i den av Euroclear Sweden AB framställda aktieboken per onsdagen den 5 maj 2021, dels ha anmält sitt deltagande genom att avge sin poströst i enlighet med anvisning under rubriken POSTRÖSTNING nedan så att poströsten är bolaget tillhanda senast onsdagen den 12 maj 2021. För att ha rätt att delta i årsstämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till årsstämman genom att avge sin poströst, låta registrera aktie